Antioxidant and Anti-inflammatory Effects of Natural Product Extracts

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 298

Special Issue Editor


E-Mail Website
Guest Editor
Organic Chemistry Unit, Department of Chemistry in Pharmaceutical Sciences, Faculty of Pharmacy, University Complutense of Madrid, Plza. Ramón y Cajal s/n, 28040 Madrid, Spain
Interests: phytomedicine; phytochemistry; natural products; drug discovery; organic and medicinal chemistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

I am pleased to inform you that I am organizing a Special Issue titled “Antioxidant and Anti-inflammatory Effects of Natural Product Extracts” for the journal Pharmaceuticals (ISSN: 1424-8247, https://www.mdpi.com/journal/pharmaceuticals). Given your distinguished expertise in this field, I warmly invite you to submit articles, short communications, or letters for this Special Issue.

Below is a brief introduction to the focus we are seeking for this Special Issue:

Inflammation is a physiological response triggered by various factors, such as pathogens or injuries. Additionally, environmental factors, including dietary choices, can contribute to lifestyle-related diseases, where chronic inflammation plays a crucial role. These diseases include cardiovascular conditions, cancer, diabetes mellitus, chronic kidney disease, non-alcoholic fatty liver disease, neurodegenerative disorders, and autoimmune diseases, among others.

Chronic inflammation often creates an environment conducive to oxidative stress, and vice versa. Oxidative stress results from an imbalance between the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) and the body's antioxidant defenses. This imbalance, combined with the action of pro-inflammatory agents, can trigger harmful inflammatory processes.

The increasing prevalence of chronic inflammatory diseases over the recent decade has intensified the search for natural compounds that exhibit both antioxidant and anti-inflammatory properties. These compounds are being explored as potential safe and effective alternatives to conventional pharmaceuticals.

Natural product extracts stand out for their chemical diversity and therapeutic potential. For instance, phenolic compounds and flavonoids have shown effectiveness in modulating inflammatory pathways and neutralizing free radicals. Similarly, terpenoids and saponins have demonstrated the ability to inhibit key enzymes involved in inflammatory processes, such as cyclooxygenases and lipoxygenases. Additional compounds, such as alkaloids and glycosides, exhibit notable antioxidant and anti-inflammatory properties by influencing specific biological pathways and regulating cellular responses.

Furthermore, natural products targeting key pharmacological pathways, such as Interleukins (IL), NF-κB, TNF-α, Nrf2, HIF-1α, SOD, and Catalase, offer significant therapeutic promise. Some extracts can modulate IL levels, affecting cytokine production and inflammatory responses. Others may impact the NF-κB signaling pathway, which is crucial for regulating inflammatory genes. Compounds that activate Nrf2 enhance antioxidant defenses, while those affecting SOD and Catalase help reduce oxidative stress and inflammation.

Finally, the application of advanced screening techniques and OMIC technologies, including lipidomics, proteomics, genomics, and metabolomics, has enabled the identification of new natural compounds with significant antioxidant and anti-inflammatory properties. These technologies provide a deeper understanding of how these compounds interact with biological systems and how they can be optimized for therapeutic applications.

This field represents unexplored potential and is a rich source of opportunities for researchers interested in discovering and developing new therapies based on natural products. We invite you to contribute your research and findings to this exciting and promising area of science.

Dr. Luis Apaza Ticona
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammation
  • oxidative stress
  • natural products
  • antioxidant properties
  • anti-inflammatory properties
  • omic technologies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 10235 KiB  
Article
Oxidative Stress, Inflammation, and Altered Lymphocyte E-NTPDase Are Implicated in Acute Dyslipidemia in Rats: Protective Role of Arbutin
by Reem S. Alruhaimi, Omnia E. Hussein, Sulaiman M. Alnasser, Mousa O. Germoush, Meshal Alotaibi, Emad H. M. Hassanein, Mohamed El Mohtadi and Ayman M. Mahmoud
Pharmaceuticals 2024, 17(10), 1343; https://doi.org/10.3390/ph17101343 - 8 Oct 2024
Abstract
Background/Objectives: Dyslipidemia is frequently linked to various disorders, and its clinical relevance is now recognized. The role of inflammation and oxidative stress (OS) in dyslipidemia has been acknowledged. This study assessed the potential of arbutin (ARB) to prevent dyslipidemia and its associated OS [...] Read more.
Background/Objectives: Dyslipidemia is frequently linked to various disorders, and its clinical relevance is now recognized. The role of inflammation and oxidative stress (OS) in dyslipidemia has been acknowledged. This study assessed the potential of arbutin (ARB) to prevent dyslipidemia and its associated OS and inflammation in rats with acute hyperlipidemia. Methods: Rats received ARB orally for 14 days and a single intraperitoneal injection of poloxamer-407 on day 15. Results: Poloxamer-407 elevated circulating cholesterol (CHOL), triglycerides (TG), very low-density lipoprotein (vLDL), and LDL, and reduced high-density lipoprotein (HDL)-C and lipoprotein lipase (LPL). ARB ameliorated the circulating lipids and LPL, and suppressed 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) in rat liver and in vitro. Fatty acid synthase (FAS) in rat liver and its in vitro activity were suppressed by ARB, which also upregulated the LDL receptor (LDL-R) and ABCA1, and had no effect on ABCG5 and ABCG8 mRNA. ARB ameliorated liver malondialdehyde and nitric oxide and enhanced antioxidants in rats with dyslipidemia. Liver NF-κB p65 and blood inflammatory cytokines were increased in dyslipidemic rats, effects that were reversed by ARB. Moreover, ARB effectively suppressed lymphocyte E-NTPDase and E-ADA activities in dyslipidemic rats. The biochemical findings were supported by in silico data showing the affinity of ARB to bind LDL-R PCSK9 binding domain, HMGCR, FAS, and E-NTPDase. Conclusions: ARB possessed anti-dyslipidemia, anti-inflammatory, and antioxidant effects mediated via the modulation of CHOL and TG synthesis, LPL, lymphocyte E-NTPDase and E-ADA, and cytokine release in rats. Thus, ARB could be an effective agent to attenuate dyslipidemia and its associated OS and inflammation, pending further studies as well as clinical trials. Full article
(This article belongs to the Special Issue Antioxidant and Anti-inflammatory Effects of Natural Product Extracts)
Show Figures

Graphical abstract

Back to TopTop